MTHFD2 and cancer: Because patients with a poor prognosis have a high risk of recurrence after surgery [33], MTHFD2-targeting therapies could be added to their treatment regimen to prevent recurrence when the expression level of MTHFD2 is high in the resected cancer tissues.